middle.news
Mesoblast’s Ryoncil Sales Jump 66% After FDA Approval and CMS Reimbursement
9:54am on Tuesday 7th of October, 2025 AEDT
•
Healthcare
Read Story
Mesoblast’s Ryoncil Sales Jump 66% After FDA Approval and CMS Reimbursement
9:54am on Tuesday 7th of October, 2025 AEDT
Key Points
Ryoncil gross revenue hits US$21.9 million in Q2 2025
66% quarter-on-quarter revenue growth post FDA approval
Permanent J-Code reimbursement by CMS effective October 1
Ryoncil is first FDA-approved MSC therapy for pediatric SR-aGvHD
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MSB
OPEN ARTICLE